Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Structural and immunogenic characterisation of ChAdOx1 Chik-derived Chikungunya VLPs supports a mechanistic rationale for vaccine-induced protection.

Npj viruses·2026

Same author

Advances in Alphavirus and Flavivirus Research II.

Viruses·2026

Same author

A novel chimpanzee-derived adenovirus, a recombinant of Mastadenovirus exoticum and Mastadenovirus blackbeardi members, reveals lineage-specific recombination hotspots in simian adenoviruses.

Virology·2026

Same author

Small extracellular vesicles from DENV2-infected C6/36 cells show viral infection <i>in vitro</i> and <i>in vivo</i>.

Emerging microbes & infections·2026

Same author

Recent Advances in Vaccine Development for Flaviviruses and Alphaviruses.

Vaccines·2025

Same author

Heterologous prime-boost Zika virus vaccination induces comprehensive humoral and cellular immunity in mouse models.

Frontiers in immunology·2025

Search research articles

Related Experiment Video

Updated: Feb 25, 2026

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Published on: October 17, 2018

Current trends in Zika vaccine development.

Francisco A Lagunas-Rangel¹, Martha E Viveros-Sandoval^1,2, Arturo Reyes-Sandoval^1,3

¹UMSNH-Oxford University Clinical Research Laboratory (UMOCRL), Faculty of Biological and Medical Sciences 'Dr Ignacio Chávez', Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Mexico.

Journal of Virus Eradication

|August 1, 2017

Summary

Zika virus (ZIKV) outbreaks escalated rapidly in the 21st century. Ongoing research focuses on developing effective ZIKV vaccines, addressing challenges like cross-reactivity with other flaviviruses.

Keywords:

Zika virus flavivirus vaccine

More Related Videos

Quantification of Antibody-dependent Enhancement of the Zika Virus in Primary Human Cells

Quantification of Antibody-dependent Enhancement of the Zika Virus in Primary Human Cells

Published on: January 18, 2019

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication

Published on: October 30, 2021

Related Experiment Videos

Last Updated: Feb 25, 2026

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Published on: October 17, 2018

Quantification of Antibody-dependent Enhancement of the Zika Virus in Primary Human Cells

Quantification of Antibody-dependent Enhancement of the Zika Virus in Primary Human Cells

Published on: January 18, 2019

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication

Published on: October 30, 2021

Area of Science:

Virology
Epidemiology
Vaccinology

Background:

Zika virus (ZIKV), first isolated in 1947, remained largely dormant for decades before causing significant outbreaks starting in 2007.
Epidemic ZIKV activity surged in the 2010s, with major events in Micronesia, French Polynesia, and widespread transmission across the Americas.

Discussion:

No licensed prophylactic vaccine is currently available for ZIKV.
Remarkable progress in vaccine development involves diverse strategies, including live-attenuated, inactivated, mRNA, and genetically engineered viral platforms.
Licensed flavivirus vaccines offer a precedent, suggesting a protective ZIKV vaccine is attainable.

Key Insights:

Vaccine development faces challenges, including potential antibody-dependent enhancement with dengue virus.
Ensuring rapid induction of protective immune responses, especially during pregnancy, is crucial.
Interactions between vaccine-induced immunity and other flaviviruses require careful consideration.

Outlook:

Continued collaboration between public and private sectors is vital for ZIKV vaccine advancement.
Addressing pre- and post-licensure challenges will be key to successful vaccine deployment.
Achieving a safe and effective ZIKV vaccine is a critical public health goal.